jRCT2031220659Recruiting
Untitled Trial
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD. (PROSPERO)
Astrazeneca K.KJapan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- Chronic Obstructive Pulmonary Disease (COPD)
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Astrazeneca K.K
- Location
- Argentina;Belgium;Bulgaria;Canada;Czech;Denmark;Finland;Hungary;India;Mexico;Netherlands;Norway;Port
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031220659
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031220659 through Pure Global AI's free database. This phase not specified trial is sponsored by Astrazeneca K.K and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD).
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.